Independent Member, Board of Directors @ Viracta Therapeutics, Inc. (March 2021 - Present)
Chief Business Officer @ Celyad Oncology (February 2020 - April 2022)
Independent Member, Board of Directors @ Sermonix Pharmaceuticals (May 2019 - October 2021)
Independent Member, Board of Directors @ Ilkos Therapeutic (January 2017 - February 2020)
Chief Business and Strategy Officer @ (May 2018 - May 2019)
Entrepreneur In Residence @ (March 2017 - May 2018)
Global Head of Business Development and Licensing and New Product Marketing, Cell and Gene Therapy Unit @ (November 2014 - March 2017)
VP, Investor Relations North America @ (January 2013 - November 2014)
VP Strategic Planning and Business Development @ (January 2009 - December 2012)
VP New Product Commercialization Marketing @ (July 2001 - January 2009)
Global Marketing Head for Solid Tumor and AutoImmune Business Unit @ (September 1991 - June 2001)
Stephen Rubino Education
Cornell University
PhD (Virology)
1980-1985
Baruch College
Master of Business Administration - MBA (Business Administration and Management, General)
Stephen Rubino Skills
Biotechnology
Business Development
Clinical Development
Clinical Trials
Commercialization
Cross-functional Team Leadership
Global Marketing
Life Sciences
Mergers
Oncology
Pharmaceutical Industry
Strategic Planning
Strategy
Drug Development
Pharmaceutical Sales
Market Access
Product Launch
Venture Capital
Mergers
Stephen Rubino Summary
Stephen Rubino, based in United States, is currently a Chief Executive Officer at Sporos Bioventures. Stephen Rubino brings experience from previous roles at Viracta Therapeutics, Inc., Celyad Oncology, Sermonix Pharmaceuticals and Ilkos Therapeutic. Stephen Rubino holds a 1980 - 1985 PhD in Virology @ Cornell University. With a robust skill set that includes Biotechnology, Business Development, Clinical Development, Clinical Trials, Commercialization and more. Stephen Rubino has 3 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Stephen Rubino?
Find contact details for 700 million professionals.